Wherever constant stress lives, so too does its more agitated and debilitating cousin: anxiety. About 31% of Americans will experience an anxiety disorder at some point in their lives. What’s more, anxiety often goes hand-in-hand with depression.
- February 10, 2020Source: Psychiatric Times
Samuel Wilkinson, MD, Assistant Professor of Psychiatry and Assistant Director of the Yale Depression Research Program, writes in Psychiatric Times about the drug esketamine, approved by the U.S. Food and Drug Administration last year as the first rapid-acting therapy for treatment-resistant depression.
- March 25, 2019
Samuel Wilkinson, MD, Assistant Professor of Psychiatry and Assistant Director of the Yale Depression Research Program, has been awarded a New Investigator Award from the International Society of CNS Clinical Trials and Methodology (ISCTM).
- February 14, 2019Source: NBC Nighly News
Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry; Director of the Yale Depression Research Program; and Co-Director of the Yale New Haven Hospital Interventional Psychiatry Service is featured in a NBC Nightly News report about the drug esketamine.
- November 30, 2018Source: The New York Times
Samuel Wilkinson, MD, Assistant Professor of Psychiatry and Assistant Director of the Yale Depression Research Program, offers perspective in a New York Times report on the use of the drug ketamine to treat patients with depression.
- July 31, 2018
Acute and longer-term outcomes using ketamine as a clinical treatment at the Yale Psychiatric HospitalSource: Biological Psychiatry
Yale researchers, including first author Samuel Wilkinson, MD, Assistant Professor of Psychiatry, describe in a paper published in Biological Psychiatry their experience providing ketamine as a clinical treatment to participants with severe and treatment-resistant mood disorders.
- April 30, 2018
Building on years of research into its use as a treatment for depression, Yale researchers are now investigating whether ketamine may help veterans suffering from severe post-traumatic stress disorder.
- March 02, 2018Source: Psychiatric News
Gerard Sanacora, MD, PhD, George D. Gross and Esther S. Gross Professor of Psychiatry, spoke to Psychiatric News about the effectiveness of NMDA-targeting antidepressants.
- February 07, 2018
The Brain & Behavior Research Foundation has named studies by three Yale School of Medicine faculty in its annual top 10 list of research advancements and breakthroughs in 2017.
- February 06, 2018Source: CBS This Morning
Gerard Sanacora, MD, PhD, Professor of Psychiatry and Director of the Yale Depression Research Program, was interviewed for a CBS This Morning report on the use of ketamine to treat depression.